Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 7:04 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 385–408 of 13,466 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Diabetic Foot Ulcers
Interventions: V.A.C. Negative Pressure Wound Therapy System; Device
Lead sponsor: KCI USA, Inc; Industry
Eligibility: 18 Years and older
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 6
States / cities: New Haven, Connecticut • South Miami, Florida • Bethlehem, Pennsylvania + 2 more

Conditions: Ovarian Neoplasms
Interventions: EGEN-001 (phIL-12-005/PPC); Genetic
Lead sponsor: EGEN, Inc.; Industry
Eligibility: 19 Years and older · Female only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Gynecologic Neoplasms, Epithelial Ovarian Cancer
Interventions: PLX2853, Carboplatin; Drug
Lead sponsor: Opna Bio LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 8
States / cities: Chicago, Illinois • Boston, Massachusetts • New York, New York + 5 more

Conditions: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, End Stage Renal Disease
Interventions: Adipose tissue biopsy; Procedure
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 18 Years to 65 Years
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2019
U.S. locations: 1
States / cities: Galveston, Texas

Conditions: Hurler Syndrome (MPS I), Hurler-Scheie Syndrome, Hunter Syndrome (MPS II), Sanfilippo Syndrome (MPS III), Krabbe Disease (Globoid Leukodystrophy), Metachromatic Leukodystrophy (MLD), Adrenoleukodystrophy (ALD and AMN), Sandhoff Disease, Tay Sachs Disease, Pelizaeus Merzbacher (PMD), Niemann-Pick Disease, Alpha-mannosidosis
Interventions: hematopoietic stem cell infusion; Biological
Lead sponsor: Talaris Therapeutics Inc.; Industry
Eligibility: Not listed
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes Mellitus, Food Insecurity
Interventions: Eat Well; Other
Lead sponsor: Duke University; Other
Eligibility: 18 Years and older
Enrollment: 2,177 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Diabetes, Hypertension
Interventions: Quinapril (Accupril) plus Alpha Lipoic Acid, accupril, placebo, accupril, alpha lipoic acid; Drug
Lead sponsor: InVasc Therapeutics, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Tucker, Georgia

Conditions: Diabetes Mellitus, Type 2, Overweight
Interventions: Aerobic exercise program - 8 weeks; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 28 Years to 55 Years
Enrollment: 29 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2006 – 2010
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Type 1 Diabetes
Interventions: Omnipod Horizon™ Automated Glucose Control System; Device
Lead sponsor: Insulet Corporation; Industry
Eligibility: 2 Years to 70 Years
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Santa Barbara, California • Denver, Colorado • Atlanta, Georgia + 1 more

Conditions: Type 1 Diabetes Mellitus, Exercise Physiology
Interventions: Standard-of-Care Guidance (SoC), Usual Care (UC), netIOB & Exercise Toolkit (NEXT), Continuous Glucose Monitoring, Continuous Ketone Monitoring; Behavioral · Device
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Pancreas Cancer, Metastatic, Pancreas Carcinoma
Interventions: STRONG intervention App, individualized remote dietitian; Other
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Diabetes Mellitus, Ketosis, Diabetic
Interventions: Ketone; Diagnostic Test
Lead sponsor: Nova Biomedical; Industry
Eligibility: 18 Years and older
Enrollment: 173 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022
U.S. locations: 1
States / cities: Medley, Florida

Conditions: Type 1 Diabetes Mellitus, Pregnancy in Diabetes
Interventions: Hybrid closed-loop therapy, Sensor-augmented pump therapy; Device
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 2
States / cities: Aurora, Colorado • Columbus, Ohio

Conditions: Type 1 Diabetes
Interventions: Victoza, Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University at Buffalo; Other
Eligibility: 18 Years to 75 Years
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Breast Neoplasms, Colonic Neoplasms, Lung Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms
Interventions: Rituximab; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2000
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Type 2 Diabetes
Interventions: Targeted Self-Monitoring Of Blood Glucose (SMBG), Provider Training, Patient Education; Other
Lead sponsor: Biomedical Research Institute of New Mexico; Other
Eligibility: 18 Years to 85 Years
Enrollment: 348 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 3
States / cities: Phoenix, Arizona • Tucson, Arizona • Albuquerque, New Mexico

Conditions: Diagnoses Disease
Interventions: Determination of risk of malignancy of these thyroid lesions; Behavioral
Lead sponsor: University of Mississippi Medical Center; Other
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Jackson, Mississippi

Conditions: Diabetes, Diabetes Mellitus, Type 2
Interventions: Faster-acting insulin aspart, Insulin aspart, Insulin degludec, Metformin; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 64
States / cities: Concord, California • Fresno, California • Fullerton, California + 56 more

Conditions: Ovarian Cancer, Sarcoma, Small Intestine Cancer
Interventions: filgrastim, docetaxel, gemcitabine hydrochloride; Biological · Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 82 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1999 – 2003
U.S. locations: 1
States / cities: New York, New York

Conditions: Microsatellite-instability (MSI) High Colorectal Cancer (CRC), Endometrial Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC), Gastric Cancer, Lung Cancer, Lymphoma, Renal Cell Carcinoma (RCC), Ovarian Cancer, Solid Tumors, UC (Urothelial Cancer), Melanoma, Bladder Cancer, Triple Negative Breast Cancer (TNBC)
Interventions: MK-3475, INCB024360; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 444 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 24
States / cities: La Jolla, California • Los Angeles, California • Sacramento, California + 19 more

Conditions: Type 1 Diabetes
Interventions: t:slim X2 insulin pump with Control-IQ technology 1.5; Device
Lead sponsor: Tandem Diabetes Care, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 4
States / cities: Aurora, Colorado • Idaho Falls, Idaho • Minneapolis, Minnesota + 1 more

Conditions: Primary Peritoneal Cavity Cancer, Stage I Endometrial Carcinoma, Stage I Ovarian Epithelial Cancer, Stage IA Cervical Cancer, Stage IB Cervical Cancer, Stage II Endometrial Carcinoma, Stage II Ovarian Epithelial Cancer, Stage IIA Cervical Cancer, Stage IIB Cervical Cancer, Stage III Cervical Cancer, Stage III Endometrial Carcinoma, Stage III Ovarian Epithelial Cancer, Stage IV Endometrial Carcinoma, Stage IV Ovarian Epithelial Cancer, Stage IVA Cervical Cancer, Stage IVB Cervical Cancer
Interventions: EF5; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older · Female only
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2005
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Diabetes, Hypertension
Interventions: Financial Incentive Group I, Financial Incentive Group II; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions: Anti-CSF1 Monoclonal Antibody PD-0360324, Cyclophosphamide, Laboratory Biomarker Analysis; Biological · Drug · Other
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Houston, Texas

Search by objective public record fields.

Evaluating the Ease of Use of a VAC GranuFoam Bridge Dressing on Diabetic Foot Ulcers Receiving VAC Negative Pressure Wound Therapy

Safety Study of phIL-12-005/PPC to Treat Recurrent Ovarian Cancer

PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer

Adipose Tissue Function After Pancreas Transplantation

Phase I/II Pilot Study of Mixed Chimerism to Treat Inherited Metabolic Disorders

Eat Well Produce Benefit for Diabetes and Food Insecurity

Effects of Quinapril 40 mg With Alpha Lipoic Acid or Placebo on Diabetes and Hypertension

Mitochondrial Dysfunction in Type 2 Diabetes Mellitus and Capacity for Fat Oxidation During Exercise

Continuous Glucose Monitoring System (CGM)-Informed Bolus Calculator Study

Using a Personalized Decision Support Tool to Help People With Type 1 Diabetes Manage Exercise

The STRONG Nutrition Support Study for People With Pancreatic Cancer

StatStrip Glucose/Ketone Meter System Ketone Evaluation

Pregnancy Intervention With a Closed-Loop System (PICLS) Study

Effects of Single Doses of Liraglutide and Dapagliflozin on Ketogenesis in Type 1 Diabetes

A Phase II Clinical Trial of Suppression of Human Antimouse Antibody and Human Antitoxin Response to Immunotoxin LMB-1 by Rituximab

Impact of Accu-Chek 360 in Veterans With Type 2 Diabetes

Atypia of Undetermined Significance (AUS) / Follicular Lesion of Undetermined Significance (FLUS)

Research Study Comparing a New Medicine "Fast-acting Insulin Aspart" to Another Already Available Medicine "NovoRapid"/"NovoLog" in People With Type 2 Diabetes

Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

Control-IQ Technology for High Insulin Users With Type 1 Diabetes (Higher-IQ)

EF5 in Finding Oxygen in Tumor Cells of Patients Who Are Undergoing Surgery or Biopsy for Cervical, Endometrial, or Ovarian Epithelial Cancer

Way to Health, Healthy Measures

PD 0360324 and Cyclophosphamide in Treating Patients With Recurrent High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer